Pamidronate decreases tumor-induced osteoclastogenesis in osteopetrotic mice.
Recent studies indicate that the bisphosphonate pamidronate reduces skeletal complications caused by tumor osteolysis. In this investigation, the cellular mechanism through which pamidronate affects tumor-induced osteoclastogenesis is studied in osteopetrotic mice. A unique animal model is employed which studies the effect of pamidronate on a tumor (2472 sarcoma) which induces osteoclastogenesis in osteoclast-deficient mice (oplop). This model provides opportunity to specifically study effects on osteoclast formation and findings suggest that pamidronate decreases the number of osteoclasts at sites of 2472 tumor by decreasing the number of osteoclast precursor cells at the level of myeloid precursors.
Clohisy
D R
DR
Department of Orthopaedic Surgery, University of Minnesota and the University of Minnesota Cancer Center, Minneapolis 55455, USA.
O' Keefe
P F
PF
Ramnaraine
M L
ML
D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology*; D017209:Apoptosis / Q000187:drug effects; D001859:Bone Neoplasms / Q000150:complications / Q000188:drug therapy / Q000473:pathology*; D001862:Bone Resorption / Q000188:drug therapy* / Q000209:etiology; D002452:Cell Count; D004164:Diphosphonates / Q000494:pharmacology*; D004195:Disease Models, Animal; D051379:Mice; D008817:Mice, Mutant Strains; D010010:Osteoclasts / Q000187:drug effects / Q000473:pathology*; D000077268:Pamidronate; D012509:Sarcoma / Q000150:complications / Q000188:drug therapy / Q000473:pathology*; D013234:Stem Cells / Q000166:cytology / Q000187:drug effects
D000970:Antineoplastic Agents; D004164:Diphosphonates; D000077268:Pamidronate